ATLANTA, June 24, 2020 (GLOBE NEWSWIRE) -- CBD products have gone mainstream and are now available in major retailers like CVS, Walgreens, and Kroger. Over the past few years many companies have announced they are getting into the CBD business, but a lot of them failed to develop a product. So, who is making all of the money from CBD? How big is the market? Chicago-based market research firm, High Yield Insights, says that by 2025, the CBD market could surpass $23.6 billion, which is a 22.2 percent growth rate. Also according to High Yield Insights, "roughly 40 percent of U.S. adults age 21 and over indicated a willingness to explore CBD under the right conditions." High Yield Insights is not the only research firm talking about big numbers; New Frontier Data conducted a nationally represented survey of consumers that said 86% of Americans know of CBD, while 18% of Americans have tried CBD at least once. Another survey with surprising results is one that was completed by the Arthritis Foundation, where 26 percent of patients with arthritis said they use CBD to treat their symptoms.
Most of the CBD products the average American consumer finds on the shelf are made from hemp. Currently, 47 of the 50 U.S. states, as well as the District of Columbia, have legalized the sale and use of hemp derived CBD products. According to federal law, hemp CBD is 100% legal and cannot contain more than 0.3 percent of THC, which is the compound in the plant most commonly associated with getting a person high. This emerging trend in the CBD market adds up to explosive growth potential for companies like Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) , Charlotte's Web Holdings, Inc. (OTCQX: CWBHF), Tilray (NASDAQ: TLRY), and Curaleaf Holdings (OTCQX: CURLF)
Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) is a fully-reporting, early stage, emerging biotech company focused on aerosol delivery of legal cannabinoids to the systemic blood stream though the pulmonary route of administration, which means you inhale it into your lungs. RTSL's main product is the RxoidTM metered dose inhaler, which is also known as an MDI. The thing that differentiates RTSL from its competitors is the delivery method of its product. The RxoidTM MDI shares many similar physical characteristics to an asthma inhaler and works the same way by delivering medication directly to a user's blood stream through the pulmonary tract. RxoidTM delivers a safe and effective dosing of hemp CBD, which is easily inhaled, to combat not only pain, but numerous forms of anxiety, including social anxiety disorder (SAD), panic disorder, obsessive-compulsive disorder, GAD, and post-traumatic stress disorder (PTSD). The device features the safest, quality ingredients designed for the fastest acting relief. RTSL markets its RxoidTM MDI product mainly through pharmacies, physicians, and select distributions chains. You can also buy direct on the Company’s website. If you want to try a RxoidTM MDI from RTSL, you can order one online at https://www.rxoid.com/product/rxoid-cbd-inhaler/.
RTSL came public late last year and announced on June 23, 2020 it had received a 100,000 unit wholesale order of its RxoidTM brand 5.0 mg proprietary CBD/CBG formulation which delivers a 98% bioavailable dose of CBD directly to the systemic blood stream. Chairman and CEO Donal R. Schmidt, Jr., Esq., said in the press release, "Our RxoidTM CBD Inhalers are currently being sold through doctors' offices and in pharmacies across the United States and we are extremely pleased about our products' acceptance throughout the medical community." MDI’s are generally sterile, stable, will not oxidize and have a long shelf life not affected by light or temperature. They require neither heat nor batteries, and are efficient devices to deliver medication to humans, whether systemically or topically. Bioavailability, which is the extent and rate at which the active drug enters systemic circulation, of RTSL’s MDI approaches 98%. RTSL is also testing CBN blends and psilocybin where legal. In our opinion, RTSL's RxoidTM product offers a tremendous alternative to CBD tablets, gummies, oils, edible food items, and capsules with oil in them. Not only does it work, RxoidTM is manufactured using Current Good Manufacturing Practice standards that are mandated by the FDA with respect to the manufacture of all drugs and medical devices. Interested investors can find out more about Rapid Therapeutic Science Laboratories, Inc. on the Company's website at www.rtslco.com, as well as in a research report written by Brian R. Connell, Chartered Financial Analyst (CFA) at Emerald Equity Research, LLC, which can be downloaded at https://emeralder.com/wp-content/uploads/2020/06/RTSL-Coverage-Initiation-Report-June-22-2020.pdf.
Charlotte’s Web Holdings, Inc. (OTCQX: CWBHF) is a Colorado-based, vertically-integrated hemp-derived CBD company, operating a 50,000 square foot in-house production and manufacturing facility on over 300 acres of irrigated farmland. Charlotte's Web Holdings make CBD oil tinctures, capsules, topicals, and CBD pet products which are sold directly on their e-commerce site, as well as through their wholesale distribution network.
On May 14, 2020, Charlotte’s Web Holdings announced organic consolidated revenue of $21.5 million for Q1 2020, which ended March 31, 2020, vs. $21.7 million in Q1 2019. Even though revenues for the quarter were fairly flat, the Company posted a gross profit of $15.0 million, which was 69.8% of consolidated revenue. As of March 31, 2020, Charlotte’s Web Holdings had $53.0 million in cash and $114.9 million in working capital, as well as a $10 million line of credit from J.P. Morgan. During Q1 2020, the Company signed on its first national pet retailer and announced its products were in nearly 12,000 retail doors.
On June 18, 2020 Charlotte's Web Holdings, Inc. announced it had closed an underwritten public offering in Canada for aggregate gross proceeds to the Company of C$77,625,000. A total of 11,500,000 units comprised of one common share of Charlotte's Web Holdings and one half of one common share purchase warrant were sold at C$6.75 per Unit
Tilray (NASDAQ: TLRY) is a Canadian-based company that supplies high-quality medical cannabis products to tens of thousands of patients in fifteen countries spanning five continents across the world through its subsidiaries in Australia, Canada, Germany, Latin America and Portugal and through agreements with established pharmaceutical distributors.
Out of the 16 analysts currently covering Tilray, 13 rate the stock as a hold. Two analysts have a buy rating on it and one analyst has it ranked as a sell. In spite of a less than enthusiastic opinion by analysts, Tilray still manages to maintain a market cap close to $1 billion. With the exception of a message regarding social issues from CEO, Brendan Kennedy, Tilray's last news was that the Company received a Good Manufacturing Practice (GMP) certification in accordance with European Union standards, for its manufacturing facility in Cantanhede, Portugal.
Curaleaf Holdings (OTCQX: CURLF) has a presence in 17 states, owns and operates 57 dispensaries, 15 cultivation sites and 24 processing sites. Curaleaf is the largest national retail dispensary brand in the U.S., as well as a premium mainstream cannabis brand available in multiple states and product formats. Curaleaf offers a complete line of hemp-based CBD products.
On June 22, 2020 Curaleaf Holdings, Inc. announced an amended agreement for its acquisition of GR Companies, Inc. ("Grassroots"), the largest private vertically-integrated multi-state operator in the United States. Under the new mutually agreed and amended terms of the agreement, the principal component of the transaction consideration remains the same at approximately 102.8 million subordinate voting shares of Curaleaf. What had initially been a $75 million cash component of the consideration has been eliminated, while the component of additional Curaleaf subordinate voting shares to be priced at the 10-day volume-weighted average price prior to closing of the transaction has been increased from $40 million to approximately $90.1 million, subject to final adjustment. Accordingly, the total subordinate voting shares consideration for the transaction is expected to be approximately 118.9 million shares.
DISLAIMER: The purpose of this release is to introduce the reader to OTCStockReview.com (OTCSR) and Rapid Therapeutic Science Laboratories, Inc. (RTSL). OTC Stock Review is not a Registered Investment Advisor, Broker, or Dealer. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice, or research material. OTCSR is not a registered broker/dealer/. OTCSR's market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. This document contains information obtained from public sources about RTSL, but does not contain all the relevant material information necessary to evaluate the company. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. This release is not an offer to buy, sell, hold, and/or otherwise trade in the securities of RTSL, as profiled. OTCSR has been compensated four thousand dollars by a third party to perform investor relations services for RTSL. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled Company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm. OTCSR holds no shares of any company named in this release.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCSR undertakes no obligation to update such statements.
OTC Stock Review
David Kugelman
404-281-8556